Alvotech Biopharmaceuticals (ALVO): Price-to-Projected Revenue Ratio
The current forward P/S ratio reflects market expectations for Alvotech, whose success depends on regulatory approvals and the outcome of patent wars. 3.70 serves as the final level mark. The business faces stringent FDA oversight and significant lobbying. Meanwhile, the high-tech plant operates at maximum efficiency, steadily expanding production capacities without equipment downtime.
Analytical breakdowns for Alvotech Biopharmaceuticals (ALVO)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- business debt structure and liquidity details:
- net income and valuation multiples indicators:
ALVO - Net Profit|Expected Profit Alvotech|ALVO - Price to Earnings Ratio|Projected Price to Earnings Alvotech Corp|ALVO - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alvotech Biopharmaceuticals|ALVO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Alvotech|ALVO - Earnings per one share for the last 12 months|Quarterly EPS earnings growth alvotech.com|ALVO - Earnings per share increase in current year|Earnings growth forecast for next year Alvotech
- sales revenue and business income indicators:
Initial company analysis:Alvotech SA ALVO
The forward P/S ratio determines the market value of a business relative to expected revenue, allowing for a real-time assessment of capitalization without waiting for quarterly reports. By analyzing the forward P/S ratio, an investor can see how Alvotech (ALVO) management's ambitions for biosimilar expansion and the disruption of monopolies are reflected in the price, which helps determine the entry point during production scaling.
Competitors of Alvotech (ALVO)
Forward P/S Multiple HLN (Haleon)|Forward P/S Multiple Kenvue Inc KVUE|VRNA - Price-to-Projected Revenue Ratio|MENS: Price-to-Projected Revenue Ratio|LGND (Ligand Pharmaceuticals) - Forward Price-to-Revenue Multiple|AMRX (amneal.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Perrigo|Market Cap to Future Revenue Ratio Liquidia Corp LQDA|Forward Price-to-Revenue Multiple GLPG (Galapagos Genomics)|Price to Expected Revenue Ratio ANIP|Forward P/S Multiple MNKD (MannKind Corporation)|amphastar.com (AMPH) - Market Cap to Future Revenue Ratio|Pacira BioSciences, Inc. - Forward P/S Multiple|ARS Pharmaceuticals Inc (SPRY) - Forward Price-to-Revenue Multiple|TBPH: Forward P/S Multiple|Aquestive Corp - Forward Price to Sales|SCPH (scPharmaceuticals, Inc.) - Forward P/S Multiple|Forward P/S Multiple Tectonic|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Holding Corp. (TNXP)|Price-to-Projected Revenue Ratio SXTC (sxtchina.com)|Eupraxia Pharmaceuticals Inc. - Forward Price-to-Revenue Multiple|BioHarvest Sciences Inc - Price-to-Projected Revenue Ratio|EXOZ - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Oramed Pharmaceuticals|enterabio.com (ENTX) - Price-to-Projected Revenue Ratio|Future Price to Revenue HYFT (MindWalk Holdings, Inc.)|ABVC (ABVC BioPharma Inc) - Forward P/S Multiple|CPIX: Forward Price to Sales|Forward P/S Multiple QNTM|Forward P/S Multiple fibrogen.com (FGEN)|Price-to-Projected Revenue Ratio Telomir Pharmaceuticals, Inc. TELO|Forward Price to Sales RANI|SNYR - Price-to-Projected Revenue Ratio|Rallybio Corporation (RLYB) - Forward Price-to-Revenue Multiple|LEXX: Forward P/S Multiple|pulmatrix.com (PULM) - Forward P/S Multiple|Forward Price-to-Revenue Multiple PTHL|APM: Forward Price to Sales|Price-to-Projected Revenue Ratio Lyra Therapeutics, Inc (LYRA)|IBO - Market Cap to Future Revenue Ratio|TNF Pharmaceuticals, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio YCBD (cbdMD Inc.)|PainReform - Forward P/S Multiple|Forward Price to Sales CYTO (Altamira Therapeutics)|LIPO: Forward P/S Multiple|Market Cap to Future Revenue Ratio OptiNose Corp (OPTN)|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|PROC: Forward Price to Sales|Forward P/S Multiple PTPI|Forward P/S Multiple Qilian International Holding Group (QLI)|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|TFF Pharmaceuticals, Inc - Price-to-Projected Revenue Ratio
